As of September 30, 2025, Cabaletta had cash, cash equivalents and short-term investments of $159.9 million, compared to $164.0 million as of December 31, 2024. The Company expects that its cash position as of September 30, 2025, will enable it to fund its operating plan into the second half of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Is CABA a Buy, Before Earnings?
- Cabaletta Bio price target raised to $30 from $15 at Cantor Fitzgerald
- Cabaletta Bio Updates on CD19-CAR T Therapy Progress
- Cabaletta Bio’s Promising Clinical Advances and Strategic Plans Earn Buy Rating from Michael Ulz
- Cabaletta Bio’s Innovative Myopathy Study: A Potential Game-Changer?